Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.
Also called NCT03159052
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 450 participants
- Registry
-
NCT03159052
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03159052. Randomized; quadruple masking; primary purpose treatment. Start 2017-06 (anticipated); primary completion 2018-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- SHR3824
- Intervention (Drug)
- Placebo
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct03159052- Content hash
c9baa972d92c488dd21df273105f770f4ce919617730dcfdbc61bbaf0f066dbb